The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its ...

Socotra, the leading provider of insurance core technology, announced today that If P&C Insurance (If), the largest property and casualty insurer in the Nordic region, has successfully launched a ...

NuxGame, a leading B2B provider of iGaming solutions, is proud to introduce its Casino API and Sports Betting API , two dynamic tools designed to empower online casino and sportsbook operators. These ...

YMAX, YMAG, FEAT and FIVY generally invest in other YieldMax™ ETFs. As such, these two Funds are subject to the risks listed ...

TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / May 28, 2025 / Organto Foods Inc. (TSXV:OGO)(OTC ...

AUSTIN, TX / ACCESS Newswire / May 27, 2025 / Volcon ePowersports (NASDAQ:VLCN) (“Volcon” or the “Company”)) the first ...